ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2023年03月02日 12時00分
Source:
Eisai
バイオジェン・ジャパンとエーザイの日本における多発性硬化症治療剤の共同販促について
東京, 2023年03月02日 - (JCN Newswire) - バイオジェン・ジャパン株式会社(本社:東京都、代表取締役社長:傳 幸諭、以下 バイオジェン・ジャパン)とエーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下エーザイ)は、2018年1月より実施していたバイオジェン・ジャパンの多発性硬化症治療剤「テクフィデラ(R)」(一般名:フマル酸ジメチル)、「タイサブリ(R)」(一般名:ナタリズマブ(遺伝子組換え))、「アボネックス(R)」(一般名:インターフェロンベーター1a(遺伝子組換え))に関する日本における共同販促契約を2023年3月末日をもって終了することをお知らせします。
これまで両社共同で情報提供活動を行ってきましたが、当該製品の市場浸透について一定の目的を達成したことから、両社合意の下、本共同販促契約を終了することとなりました。本共同販促契約の終了に伴い、両社による引継ぎ期間を経て、バイオジェン・ジャパンが、当該製品に関するすべての業務を行うこととなります。また、本共同販促契約の終了にあたり、バイオジェンはエーザイに31 million USDを支払います。
なお、本件はバイオジェンとエーザイの間の他の契約には影響しません。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2023/news202315.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Anime Tokyo Station: Mobile Suit Gundam GQuuuuuuX -Beginning- Special Exhibition
May 03, 2025 03:00 JST
TOYOTA GAZOO Racing Set for Spa spectacle
May 02, 2025 19:29 JST
FWD Group reports exceptionally strong first quarter new business update
May 02, 2025 17:00 JST
Toyota Mobility Foundation, Bangkok Metropolitan Administration, UN-Habitat, Asian Institute of Technology and Toyota Motor Thailand Sign a Letter of Intent (LOI) to Launch the TRUST Project for Road Safety in Thailand
May 01, 2025 17:48 JST
Katalon Officially Launches TrueTest(TM) - The First AI-Native Testing System That Thinks Like a Tester and Learns from Users
Apr 30, 2025 17:20 JST
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
Apr 30, 2025 14:17 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of Large Car Ferry KEYAKI in Shimonoseki
Apr 29, 2025 17:24 JST
NEC DGDF Headquarters relocates to Zurich to accelerate growth and enhance management globally
Apr 28, 2025 16:03 JST
NEC achieves Japan's longest terrestrial wireless optical communication over 10 km
Apr 25, 2025 17:50 JST
Olympus Appoints New CEO
Apr 25, 2025 15:30 JST
DENSO Announces Year-End Financial Results
Apr 25, 2025 12:17 JST
DENSO and DELPHY Sign Memorandum of Understanding to Develop Data-Driven Smart Horticulture
Apr 24, 2025 18:43 JST
MyJCB App Wins "iF DESIGN AWARD 2025"
Apr 24, 2025 17:00 JST
Fujitsu launches new company 1FINITY to strengthen network products business
Apr 24, 2025 16:24 JST
MHIEC Completes Renovation of Core Facilities for Arita Municipal Recycle Plaza in Saga Prefecture
Apr 24, 2025 15:01 JST
NEC invests in U.S.-based "Geodesic Alliance Fund" aiming to strengthen economic security business
Apr 24, 2025 10:23 JST
MHI Thermal Systems Wins German Red Dot Design Award 2025
Apr 24, 2025 10:11 JST
ULVAC Develops Dilution Refrigerator for Quantum Computers
Apr 24, 2025 09:30 JST
Fujitsu expands strategic collaboration with Supermicro to offer total generative AI platform
Apr 23, 2025 11:55 JST
Furuya Metal and Asahi Kasei Embark on Demonstration Trial Regarding Recycling of Metals for Chlor-alkali Electrolysis Cells and Electrodes
Apr 23, 2025 11:00 JST
More Latest Release >>
Related Release
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
4/30/2025 2:17:00 PM JST
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
4/18/2025 4:52:00 PM JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
4/1/2025 1:15:00 PM JST
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
3/25/2025 5:28:00 PM JST
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
3/25/2025 12:21:00 PM JST
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
3/10/2025 8:24:00 PM JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
3/5/2025 9:09:00 AM JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
3/4/2025 5:22:00 PM JST
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
3/3/2025 3:41:00 PM JST
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
3/3/2025 1:53:00 PM JST
More Press release >>